Comparable stake leader
William J. Link PhD
SEC ownership of Oyster Point Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001720725.
Disclosed value leader
William J. Link PhD
Comparable rows
0/2
Latest evidence
09 Jan 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
William J. Link PhD
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
09 Jan 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001720725
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Oyster Point Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
William J. Link PhD
Disclosed value leader
William J. Link PhD
Comparable rows
0/2
Latest evidence
09 Jan 2022
3/4/5
Highest disclosed value: $5,467,492
2 rows are not safely comparable across share classes.
Quick read
William J. Link PhD has the largest disclosed position value at $5.47M.
0 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens William J. Link PhD's linked filing trail.
Disclosed position value
Top 2
William J. Link PhD
$5.47M
John Snisarenko
$339.6K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| William J. Link PhD |
3/4/5
Director
|
—
class O/S missing
|
$5,467,492
488,169 shares
|
— | 05 Jan 2022 |
| John Snisarenko |
3/4/5
Chief Commercial Officer
|
—
mixed-class rows
|
$339,606
84,822 shares
mixed-class rows
|
— | 09 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Oyster Point Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
William J. Link PhD
Net 12M change
$0
Latest report
03 Jan 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| William J. Link PhD | Director | $5,467,492 | Mixed | 05 Jan 2022 | ||
| John Snisarenko | Chief Commercial Officer | $339,606 | Mixed | 09 Jan 2022 | ||
| Benjamin Tsai | Director | Mixed | 03 Jan 2023 | |||
| InvOpps GP IV, L.L.C. | Director, 10%+ Owner | Mixed | 03 Jan 2023 | |||
| Aimee S. Weisner | Director | Mixed | 03 Jan 2023 | |||
| Versant Venture Capital VI, L.P. | 10%+ Owner | Mixed | 03 Jan 2023 | |||
| Donald J. Santel | Director | Mixed | 03 Jan 2023 | |||
| Mark Anthony Murray | Director | Mixed | 03 Jan 2023 | |||
| Daniel Lochner | Chief Financial Officer | Mixed | 01 Dec 2022 | |||
| Jeffrey Nau | President and CEO, Director | Mixed | 01 Dec 2022 | |||
| New Enterprise Associates 14, L.P. | 10%+ Owner | Mixed | 03 Jan 2023 | |||
| Michael G. Atieh | Director | Mixed | 03 Jan 2023 | |||
| Ali Behbahani | Director | Mixed | 03 Jan 2023 | |||
| Clare Ozawa | Director | Mixed | 03 Jan 2023 | |||
| George Christopher Eliades | Director | Mixed | 03 Jan 2023 |
Recent insider transactions for Oyster Point Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.